ELSEVIER

Contraception

Contraception 65 (2002) 449–450

Author Index
Volume 65
January-June 2002

Alvarez, F., 63, 121
Arévalo, M., 333
Artico, M., 277
Artz, L., 151
Assmann, A., 207

Baccetti, B., 283
Bahamondes, L., 129, 325
Bai, J.-P., 441
Ballan, A., 165
Barnhart, K., 343
Bauer, H. H., 223
Benzi, G., 425
Best, K., 385
Bevilacqua, E., 171
Blumenthal, P. D., 415
Boitani, C., 301
Bolle, P., 313
Bonanomi, M., 317
Brache, V., 63, 121

Capitani, S., 283
Carr, B. R., 397
Castleman, L., 415
Cerpolini, S., 269
Chan, J., 159
Chen, Y., 177
Cheng, C. Y., 265, 305
Cheng, L., 237
Chiarenza, C., 289
Chien, Y. W., 435
Chikamata, D. M., 97
Cipriani, S., 425
Cochon, L., 63, 121
Collodel, G., 283
Constantino, A., 269
Cotton, S., 403
Coutinho, E. M., 259
Cronin, M., 215
Croxatto, H. B., 15, 21, 121
Curtis, K. M., 85

Dalkalitsis, N., 339
Dantas-Monteiro, C., 129
d'Arcangues, C., 75
Davis, A. R., 351
Debnath, J. M., 379
Deeb, M. E., 165
Degani, S., 411
DelConte, A., 397
Dell'Omo, G., 273
Demand, M., 151
Dewachi, O., 165
Diaz, J., 129, 325
Díaz, S., 39
Diaz-Olavarrieta, C., 143
Dickey, R. P., 447
Dondero, F., 301
Dorflinger, L. J., 47
Dubey, R. K., 231
Düsterberg, B., 215

Edström, B., 187
El-Kak, F., 165
Ellertson, C., 133, 143
Elton, R., 237
Endrikat, J., 215
Ersheng, G., 365
Espey, E., 389
Evandri, M. G., 313
Ezcurra, E., 143

Faghihzadeh, S., 329
Faundes, A., 63, 121
Fielding, S., 369
Filippini, A., 289
Fong, S., 159
Fuentealba, B., 121

Gandini, L., 301
Garavaglia, E., 425
Gatto, M. T., 277
Gerlinger, C., 215
Gesouli, E., 339
Ghosh, D., 379
Glasier, A., 29, 237
Grima, J., 265
Grimes, D. A., 321
Gross, U. H., 223
Guarnerio, P., 425

Haq, H. A., 293
Harper, C., 133
Heinemann, L. A. J., 207
Helmerhorst, F. M., 321
Helzner, J. F., 143
Hickey, M., 75
Hidalgo, M., 129
Honkanen, H., 419

Isidori, A., 279
Islam, M.A., 429

Jäger, A. W., 231
Jana, D., 379
Jennings, V., 333
Jianguo, T., 365
Jordan, A., 3
Junqing, W., 365

Kalantaridou, S. N., 339
Kamudhamas, A., 407
Kangshou, Y., 365
Kaponis, A., 339
Katzel, S., 369
Keller, P. J., 231
Khan, M. A., 429, 447
Klipping, C., 215
Korkontzelos, I., 339
Kreiner, S., 187, 197
Kuhl, H., 223
Kutschera, E., 223

Lamyian, M., 329
La Vecchia, C., 425
Lee, C. H., 435
Lee, J. H., 223
Lenzi, A., 301
Leone, M. G., 293
Levitan, Z., 411
Lewis, M. A., 207
Lidegaard, Ø., 187, 197
Liu, Z., 177
Liwei, B., 365
Lolis, D. E., 339
Lombardo, F., 301
Lu, C., 365
Lucente, G., 317

Macaluso, M., 151
Mangili, G., 425
Mannan, H. R., 357
Mantovani, A., 297
Maresca, V., 301
Massai, R., 121
Mauck, C., 343
Meirik, O., 1

0010-7824/02/$ – see front matter © 2002 Elsevier Science Inc. All rights reserved.
PII: S0010-7824(02)00361-X

Mellinger, U., 223
Meriggiola, M. C., 269
Merki-Feld, G. S., 231
Miller, S., 97
Mo, M.-y., 265, 305
Montanari, T., 171
Monteiro, I., 325
Moore, C., 223
Moo-Young, A., 113
Mouzakioti, E., 339
Mruk, D., 265, 305
Myntti, C., 165

Naito, K., 245
Nowygrod, S., 351

Ogburn, T., 389
Ohel, G., 411
Ortayli, N., 107

Palmery, M., 273
Palombi, F., 289
Panfili, E., 301
Paraskevaidis, E., 339
Parazzini, F., 425
Paz, B., 411
Peng, J-p., 177
Peng, W., 251
Petrelli, G., 297
Petta, C., 129, 325
Perrotti, M., 129, 325
Picardo, M., 301
Piomboni, P., 283
Polverino, G., 425
Posner, S. F., 151
Pretorius, E. S., 343
Pulbutr, P., 373
Pulley, L. V., 151

Qiuying, Y., 365

Rajaei, L., 329
Ricci, E., 425
Rivera, R., 385
Rocchietti March, M., 279
Rogers, M. K., 415
Rosenthal, S. L., 403
Rosselli, M., 231
Ru-Jin, Z., 251
Ruebig, A., 215

Sabo, E., 411
Salerio, B., 425
Salvatierra, A. M., 121
Saso, L., 265, 277, 293, 313
Schaff, E., 369
Schmidt, W., 215
Schulz, K. F., 321
Sent, L., 159
Shabsigh, R., 351
Shastri, P. V., 9
Shi, Y.-L., 441
Shin, S.-C., 435
Shiraishi, K., 245
Silvestrini, B., 257, 265, 305, 317
Sinai, I., 333
Siripakarn, Y., 407
Sivin, I., 113
Smith, K. B., 237
Soler, M., 415
Sookvanichsilp, N., 373
Strehler, E., 283
Succop, P. A., 403

Takihara, H., 245
Tal, T., 411
Thiel, C., 207
Timbers, K., 343

Tita, B., 265, 277
Todd, C. S., 415
Tramer, F., 301
Trottier, D. A., 429
Tsanadis, G., 339
Turner, A. N., 143

van der Spuy, Z. M., 237
van Vliet, H. A. A. M., 321
Visutakul, P., 407
von Hayn, C., 223
von Hertzen, H., 419
Vural, G., 347

Wanchick, A. M., 403
Wang, Y., 435
Wanichsetakul, P., 407
Watanaruangkovit, P., 407
Wei, Y., 365
Weiqun, L., 365
Westhoff, C., 351
Wiebe, E. R., 159
Wiegratz, I., 223
Wimberly, Y. H., 403
Winikoff, B., 133
Winkler, U. H., 223

Xiao-Bin, H., 251
Xin-Chang, Z., 251

Yang, Y., 177
Yi-Xun, L., 251
Yumei, Z., 365
Yurdakul, M., 347
Yuxian, L., 365

Zhao-Yuan, H., 251
Ziaei, S., 329
Zikopoulos, K., 339

ELSEVIER

Contraception

Contraception 65 (2002) 451–453

Subject index
Volume 65
January-June, 2002

Adverse events, implant contraceptives, 63
Androgen-progestin combination, male contraception, 269
Antenatal contraceptive advice, impact on contraceptive use, 237
Antispermatogenic activity, lonidamine (rat), 277
Attitudes and experiences, OC use, 403

Bacteriological cultures, removed IUDs, 339
Barrier contraceptive device, Lea's Shield, 343
Barriers to use, oral contraceptives, 159
Biphasic vs. triphasic OCs, 321
Bleeding pattern,
  effect of implant contraceptives, 75
  effect of levonorgestrel IUD, 129
Bone mineral density, effect of steroid hormonal contraceptives, 407
Breast feeding and contraceptive implants, 39
Buccal misoprostol, second trimester abortion, 415

Celecoxib, effect on implantation (rat), 373
Cerebral thrombosis, effect of OCs, 197
Cervical mucus, effect of chelating agents, 435
Chelating agents, effect on cervical mucus, 435
Clinical performance, effect of levonorgestrel IUD, 129
Clinical studies, progestin implants, 15, 29
Clinical supervision, role in medical abortion process, 133
Coitus interruptus/withdrawal, male role in reproductive health, 165
Consensus statement, intrauterine contraception, 385
Contraceptive implants and breastfeeding, 39
Contraceptive method choice, determinants, 357
Contraceptive use,
  eligibility criteria, 397
  value of antenatal counseling, 237
Copper T380A, textbook presentations, 389

Depot-medroxyprogesterone acetate, effect on bone mineral density, 407
Determinants, contraceptive method choice, 357

Emergency contraception practices, Latin America and the Caribbean, 143
Emergency contraceptive, Yuzpe regimen, 121
Endothelial function, effect of OCs, 231
Endothelin-1, effect on myoid cell contraction, 289
Environmental risk factors, effects on male fertility, 297
Ethinylestradiol + dienogest, effect on lipid metabolism, 223
Ethinylestradiol + estradiol valerate + dienogest, effect on lipid metabolism, 223
Ethinylestradiol + gestodene, effect on markers of endothelial function and lipids, 231
Ethinylestradiol + levonorgestrel,
  attitudes and experience, 403
  effect on lipid metabolism, 223
  effect on markers of endothelial function and lipids, 231
  metabolic effects, 215
  side effects by oral and vaginal administration, 329
  use in older women, 397

Factors in contraceptive method choice, 357
Family planning,
  role of nurses, 347
  Standard Days Method, 333
  Female condom, insertion difficulty, 151
  Fertility control, antispermatogenic agents, 273

Gossypol, male contraceptive, 259

Heat stress, effect on testis (monkey), 251

Implant contraceptives,
  progestins, 3, 15, 21, 29, 47, 63, 75, 85
  recent developments, 113
  service delivery system, 97
  toxicology of polymers, 9
  user perspectives, 107
Implantable contraceptives, commentary, 1
Implantation,
  effect of celecoxib (rat), 373
  effect of indomethacin (rat), 373
Inconsistent use of OCs, contributing factors, 429
Indazole-carboxylic acids,
  antispermatogenic activity (rat), 277
  male contraception (rat), 265
Indomethacin, effect on implantation (rat), 373
Injectable contraceptive, depot-medroxyprogesterone acetate, 407
Insertion difficulty, female condom, 151
Interferon gamma, effect on pregnancy (rabbit), 177
Intrauterine contraception, consensus statement, 385
Intrauterine device (IUD),
  effect on pelvic inflammatory disease, 339
  levonorgestrel-releasing, 129
  textbook presentations, 389
Intrauterine system, releasing levonorgestrel, 325

0010-7824/02/$ – see front matter © 2002 Elsevier Science Inc. All rights reserved.
PII: S0010-7824(02)00362-1

Laminaria, second trimester abortion, 411, 415
Lea's Shield,
  silicone rubber vaginal barrier contraceptive device, 343
  use of MRI to determine position, 343
Levonorgestrel, intrauterine system, 325
Levonorgestrel IUD, effect on bleeding patterns, 129
Lipid levels, effect of OCs, 231
Lipid metabolism, effect of dienogest-containing OCs, 223
Lipocalin type prostaglandin D-synthase, role in male fertility, 293
Lonidamine, antispermatogenic activity (rat), 277
Lonidamine analogs, male contraception (rat), 265

Male antifertility effect, *Tripterygium wilfordii* (mouse), 441
Male contraception,
  gossypol, 259
  indazole carboxylic acids (rat), 265
  introduction, 257
  lonidamine analogs (rat), 265
Male fertility,
  chemical structures in pharmacological research, 317
  effect of superoxide dismutases, 305
  effect of vitamin E, 313
  environmental risk factors, 297
  role of lipocalin type prostaglandin D-synthase, 293
Male hormonal contraception, recent advances, 269
Male role in reproductive health, coitus interruptus, 165
Male sterility, new frontiers in treatment, 279
Maytenus ilicifolia Mart., effect on pregnancy (mouse), 171
Mechanism of action, progestin implants, 21
Medical abortion,
  mifepristone + misoprostol, 133, 419
  user perspectives, 419
Menorrhagia, effect of intrauterine system releasing levonorgestrel, 325
Metabolic effects,
  ethinylestradiol + levonorgestrel, 215
  progestin implants, 47
Methodological issues, epidemiological studies on venous thromboembolism, 207
Mifepristone + misoprostol,
  medical abortion, 419
  role of clinical supervision, 133
Misoprostol, second trimester abortion, 411
Misoprostol following laminaria, second trimester abortion, 411
Mode of action, Yuzpe regimen, 121
MRI (magnetic resonance imaging)
Myoid cell contraction, effect of endothelin-1, 289

Natural family planning, Standard Days Method, 333
Nonmenstrual adverse events, implant contraceptives, 63
Nurses, role in family planning, 347

OC use and trophoblastic disease risk, 425
OC use, effect on bone mineral density, 407
Older women, use of ethinylestradiol + levonorgestrel, 397
Oral contraceptives (OC),
  barriers to use, 159
  biphasic vs. triphasic, 321
  ethinylestradiol + dienogest, 223
  ethinylestradiol + estradiol valerate + dienogest, 223
  ethinylestradiol + gestodene, 231
  ethinylestradiol + levonorgestrel, 215, 223, 231, 329, 397, 403
  predictors of inconsistent use, 429
Oral contraceptives and cerebral thrombosis, 197
Oral contraceptives and venous thromboembolism, 187
Ovarian function, effects of Yuzpe regimen, 121

Pelvic inflammatory disease, effect of IUD, 339
Pharmacological research, male fertility, 317
Polymers, toxicology studies of implant contraceptives, 9
Polyunsaturated fatty acid pattern, sperm membrane, 301
Pregnancy,
  effect of interferon gamma (rabbit), 177
  effect of *Maytenus ilicifolia* Mart. (mouse), 171
Progestin implants,
  adverse events, 63
  clinical studies, 15, 29
  effect on bleeding pattern, 75
  mechanism of action, 21
  metabolic effects, 47
  safety, 85
Progestogens, toxicology studies, 3
Prostaglandin F2α following laminaria, second trimester abortion, 411

Recent advances,
  hormonal male contraception, 269
  human sperm pathology, 283
Recent development, implant contraceptives, 113
Reference values, semen quality, 365
Removed IUDs, bacteriological cultures, 339
Rheological property, cervical mucus, 435

Safety, implant contraceptives, 85
Second trimester abortion,
  buccal misoprostol, 415
  laminaria, 415
  laminaria + misoprostol, 411
  laminaria + prostaglandin F2α, 411
Semen quality, Chinese men, 365
Seminferous tubule contractility, 289
Service delivery system, implant contraceptives, 97
Sexual behavior, influence of vaginal bleeding, 351
Side effects, OC administered by oral and vaginal route, 329
Slip-Coat™ cannula, use in surgical abortion, 369
Sperm membrane, fatty acid pattern, 301
Sperm pathology, recent advances, 283
Spermatogenic cells, effect of *Tripterygium wilfordii* (mouse), 441
Spermatogenesis, after vasectomy and vasovasostomy, 245
Standard Days Method™, efficacy, 333

Stephania hernandifolia leaf extract, effect on testicular activities (rat), 379
Superoxide dismutases,
effect on testis, 305
role in male fertility, 305
Surgical abortion, use of Slip-Coat cannula, 369

Testicular activities, effect of leaf extract of *Stephania hernandifolia* (rat), 379
Testis, effect of heat stress and testosterone undecanoate (monkey), 251
Testosterone undecanoate, effect on testis (monkey), 251
Textbook presentations, intrauterine devices, 389
Toxicology studies,
polymers used in implant contraceptives, 9
progestogens, 3
Traditional methods of contraception, 347
Treatment of male sterility, new frontiers, 279
Triphasic vs. biphasic OCs, 321
Triptergium wilfordii Hook.f.,
effect on CA^{2+} channels in spermatogenic cells (mouse), 441
Trophoblastic disease risk and OC use, 425

User perspectives,
implant contraceptives, 107
medical abortion, 419

Vaginal administration, side effects of contraceptive pills, 329
Vaginal bleeding, influence on sexual behavior, 351
Vasectomy and reversal, effect on spermatogenesis, 245
Venous thromboembolism,
effect of OCs, 287, 207
methodological issues of epidemiological studies, 207
Vertebrate pest species, fertility control, 273
Vitamin E, effect on male fertility, 313

Withdrawal/coitus interruptus, male role in reproductive health, 165

Yuzpe regimen, emergency contraception, 121